2 studies found for:    20385792 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
2 Active, not recruiting Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: dexamethasone

Indicates status has not been verified in more than two years